AirSculpt Technologies Inc. Common Stock (AIRS)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

AirSculpt is a small healthcare-services operator selling elective body contouring. I look first for durable economics. Here revenue has been shrinking: in fiscal 2023, the year ended 2023-12-31, revenue was $195.9 million; in fiscal 2024, the year ended 2024-12-31, revenue was $180.3 million; and in fiscal 2025, the year ended 2025-12-31, revenue was $151.8 million. Net income was negative in each of those years: -$4.2 million, -$8.0 million, and -$11.7 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $42.9 million and net loss was $1.1 million, or -$0.02 diluted EPS. That is not a compounding machine; it is a business still searching for profitability. The latest quarter shows some stabilization versus fiscal Q1 2026, when revenue was $39.4 million and net loss was $2.4 million, but the trend is not convincing. Free cash flow is only $760,000 on a trailing basis, a 0.7% FCF yield on the $116.8 million market cap, so cash generation is thin. Debt/equity of 0.67 adds risk. The Altman Z-score of 0.65 and negative ROE/ROCE are warning signs. At the 2026-10-13 close of $1.62, FairStock calculations show a P/B of 1.10 and a P/E of -9.00; the computed Lynch category is none because it has lost money in each of the last four years. A low price is not the same as value. There may be asset or turnaround appeal, but without a moat, pricing power, or consistent profits, I see speculation rather than a Graham-style bargain. I would want evidence of durable positive free cash flow and a stronger balance sheet before calling it a sound investment.

In plain English: AirSculpt runs clinics in the U.S. and Canada that provide minimally invasive body contouring procedures. The business looks weak right now: sales have been falling and it has lost money in each of the last four years, with very little cash left over after running the business. At $1.62 a share, the price is far below its 52-week high; it does not look clearly cheap or expensive because the stock trades near its accounting value, but continuing losses make the low price risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K/A (period ended 2025-12-31) · FY2024 10-K/A (period ended 2024-12-31) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer